West Pharmaceutical Services (United States)
WST
$353.08
-0.20%
West Pharmaceutical Services, Inc. is a leading global supplier of containment and delivery systems for injectable drugs, serving pharmaceutical, biotechnology, and generic drug manufacturers with products such as elastomer stoppers, seals, plungers, and auto-injectors. The company operates in two segments—proprietary products (about 80% of revenue) and contract-manufactured products—and generates roughly 55% of its revenue internationally. West holds a dominant position in the high-barrier packaging niche, benefiting from the rapid growth of GLP-1 receptor agonists and large-molecule biologics that require advanced delivery systems. The current investor narrative centers on the company's ability to capitalize on the booming GLP-1 market, as evidenced by its strong Q1 2026 earnings beat and raised full-year guidance, while also managing capacity expansion and potential competitive pressures.…
WST
West Pharmaceutical Services (United States)
$353.08
Related headlines
Investment Opinion: Should I buy WST Today?
We rate WST as a Hold. The company has strong fundamentals and is well-positioned in the GLP-1 supply chain, but the current valuation leaves limited upside. The average analyst target of $404.73 implies a 14.6% upside, which is modest given the risks. The strong buy consensus (1.44) is supportive, but the wide target range suggests significant uncertainty.
Sign up to view all
WST 12-Month Price Forecast
The AI assessment is neutral, as the strong growth is offset by a high valuation. The stock's forward PE of 35.4x is justified only if growth remains above 20%, but the PEG ratio of 34x suggests the market is pricing in perfection. The analyst consensus is bullish, but the wide target range indicates uncertainty. I would upgrade to bullish if revenue growth accelerates above 25% and the forward PE remains below 30x. I would downgrade to bearish if growth decelerates below 15% or if the stock breaks below its 50-day moving average.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on West Pharmaceutical Services (United States)'s 12-month outlook, with a consensus price target around $404.73 and implied upside of +14.6% versus the current price.
Average Target
$404.73
0 analysts
Implied Upside
+14.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$340 - $459
Analyst target range
The target price range spans from a low of $340.00 to a high of $459.00, representing a wide spread of $119.00, which indicates significant uncertainty about the stock's future performance. The low target of $340.00 is below the current price, suggesting that some analysts see downside risk, possibly due to concerns about valuation or competition. The high target of $459.00 implies a 30.0% upside, likely assuming continued GLP-1-driven growth and successful capacity expansion. The wide range reflects the debate over the sustainability of West's growth and the potential for multiple compression. With 15 analysts, coverage is substantial, but the recent upgrade from Barclays and the strong buy consensus suggest that the overall sentiment is positive, though the wide target spread highlights the inherent uncertainty in the stock's valuation.
Drowning in data?
Find the real signal!
Bulls vs Bears: WST Investment Factors
West Pharmaceutical presents a compelling growth story driven by the GLP-1 boom, with accelerating revenue, strong analyst support, and a solid balance sheet. However, the stock's valuation is stretched, trading at 40x trailing earnings, and the PEG ratio of 34x signals that growth expectations are extremely high. The bull case is supported by tangible revenue acceleration and a dominant market position, while the bear case hinges on valuation risk and competitive threats. The key tension is whether West can sustain its high growth rate to justify its premium multiple; any slowdown could trigger a significant de-rating. Currently, the evidence slightly favors the bulls given the strong fundamental momentum, but the risk-reward is balanced at these levels.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 21.0% YoY to $844.9M, up from 8.0% growth in Q1 2025, driven by GLP-1 demand. This acceleration supports raised full-year guidance and signals sustained momentum.
- Strong Analyst Consensus: With a Strong Buy rating (mean 1.44) and an average target of $404.73, analysts see 14.6% upside from the current $353.08. The high target of $459 implies 30.0% upside, reflecting confidence in GLP-1 tailwinds.
- Dominant Market Position: West holds a leading share in high-barrier packaging for injectables, benefiting from the rapid growth of GLP-1 and large-molecule biologics. Its proprietary products segment (80% of revenue) is the primary growth engine.
- Healthy Balance Sheet: Debt-to-equity is a low 0.13, and the current ratio is 3.02, indicating strong liquidity. This financial flexibility supports capacity expansion and potential shareholder returns.
Bearish
- Elevated Valuation: Trailing PE is 40.3x and forward PE is 35.4x, well above the market average. The PEG ratio of 34.0x is extremely high, suggesting the stock is priced for perfection and vulnerable to multiple compression.
- High Customer Concentration: A significant portion of revenue comes from a few large pharmaceutical customers, particularly those producing GLP-1 drugs. Any loss of a major customer or shift in their supply chain could materially impact revenue.
- Competitive Pressures: The success of GLP-1 drugs has attracted competitors to the packaging space, potentially eroding West's market share. New entrants could offer lower-cost alternatives, pressuring margins.
- Capacity Expansion Risks: To meet GLP-1 demand, West is investing heavily in capacity. If demand growth slows or projects face delays, the company could face overcapacity and lower returns on invested capital.
WST Technical Analysis
West Pharmaceutical's stock is in a strong long-term uptrend, with a 1-year price change of +45.5%, significantly outperforming the S&P 500's +20.5% over the same period. The current price of $353.08 sits at 91.5% of its 52-week range (between $223.83 and $386.00), indicating the stock is trading near its highs, reflecting robust momentum but also potential overextension. The stock has recovered sharply from its 52-week low, and its relative strength versus the S&P 500 over 1 year is +25.0 percentage points, underscoring its leadership within the healthcare sector.
Beta
1.14
1.14x market volatility
Max Drawdown
-24.8%
Largest decline past year
52-Week Range
$224-$386
Price range past year
Annual Return
+45.5%
Cumulative gain past year
| Period | WST Return | S&P 500 |
|---|---|---|
| 1m | -1.5% | +3.6% |
| 3m | +11.6% | +2.7% |
| 6m | +46.4% | +11.4% |
| 1y | +45.5% | +18.7% |
| ytd | +27.7% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WST Fundamental Analysis
West's revenue growth is accelerating, with Q1 2026 revenue of $844.9 million, up 21.0% year-over-year, compared to 8.0% growth in Q1 2025. The company has consistently grown revenue over the past five quarters, from $698.2 million in Q1 2025 to $844.9 million in Q1 2026, driven by strong demand for GLP-1 related components and high-value proprietary products. The proprietary products segment, which generated $694.3 million in Q1 2026, is the primary growth engine, benefiting from increased adoption of advanced drug delivery systems. This acceleration supports the company's raised full-year guidance and suggests that the GLP-1 tailwind is translating into sustained revenue growth.
Quarterly Revenue
$844900000.0B
2026-03
Revenue YoY Growth
+21.0%
YoY Comparison
Gross Margin
35.1%
Latest Quarter
Free Cash Flow
$458000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WST Overvalued?
Given West's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 40.3x, while the forward PE is 35.4x, indicating that the market expects earnings growth of about 13.7% over the next year. The PE gap of 4.9x suggests that investors are pricing in continued strong growth, but the forward multiple is still elevated, reflecting optimism about the GLP-1 opportunity. The PEG ratio of 34.0x is extremely high, implying that the stock's growth rate is not sufficient to justify its current valuation on a PEG basis, which may signal overvaluation if growth decelerates.
PE
40.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 30x~53x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include the company's high valuation, which leaves little room for error. With a trailing PE of 40.3x and a PEG ratio of 34.0x, any earnings miss could lead to a sharp multiple contraction. The company's net margin of 16.1% is healthy, but it is dependent on continued volume growth to maintain operating leverage. Additionally, West's free cash flow of $458M TTM is positive, but capital expenditures for capacity expansion could pressure cash flows if demand disappoints. The low debt-to-equity of 0.13 provides a cushion, but the company's reliance on a few large customers for a significant portion of revenue is a concentration risk that could impact financial stability if a key customer reduces orders.
